<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597323</url>
  </required_header>
  <id_info>
    <org_study_id>DC84611</org_study_id>
    <nct_id>NCT01597323</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy Evaluation of a Radiofrequency &amp; Laser/Light System for Improvement of Skin Texture</brief_title>
  <official_title>Safety and Efficacy Evaluation of the eTWO System for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Candela Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Candela Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the clinical performance, safety and efficacy, of a Radiofrequency and Laser/Light
      based device for the treatment of facial wrinkles.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Skin Texture Irregularities</condition>
  <condition>Facial Skin Wrinkles</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <description>Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Optional biopsy, for consenting subjects, of facial skin tissue from areas directly in front
      of ear (Pre-Auricular)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial
        photodamage (sun damage) and presence of mild to moderate facial wrinkling
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female between the ages of 35 and 60

          2. Non-smoker

          3. Fitzpatrick skin type I-VI

          4. Fitzpatrick Degree of Elastosis Score of 2-6 (inclusive)

          5. Presence of mild to moderate photodamage, such as solar lentigines, dyschromia and/or
             presence of mild to moderate facial wrinkling

          6. Able and willing to comply with all visit, treatment and evaluation schedules and
             requirements

          7. Able to understand and provide written Informed Consent

          8. Women of child-bearing age are required to be using a reliable method of birth control
             at least 3 months prior to study enrollment.

        Exclusion Criteria:

          1. Pregnant or intending to become pregnant during the course of study. A urine pregnancy
             test will be given to women of childbearing potential and performed during initial
             visit;

          2. Having any active electrical implant anywhere in the body, such as a pacemaker or an
             internal defibrillator

          3. Having a permanent implant in the treated area, such as metal plates and screws

          4. Unable or unlikely to refrain from tanning, including the use of tanning booths,
             during the course of the study

          5. Prior use of retinoids in treated area within 2 weeks of initial treatment or during
             the course of the study

          6. Use of oral Isotretinoin (AccutaneÂ®) within 6 months of initial treatment or during
             the course of the study

          7. Patient on systemic corticosteroid therapy 6 months prior to and throughout the course
             of the study

          8. Having received a facial dermabrasion or chemical peel treatment within 3 months of
             treatment or during the study

          9. Prior skin treatment with laser in treated area within 3 months of initial treatment
             or during the course of the study

         10. Prior use of Botox, collagen, fat injections and /or other methods of skin
             augmentation (enhancement with injected or implanted material) in treated area within
             3-4 weeks of initial treatment or during the course of the study. Treatment may not be
             performed at all over permanent dermal implants

         11. Prior ablative resurfacing procedure, brow lift, blepharoplasty or face lift in
             treated area with laser or other devices within 12 months of initial treatment or
             during the course of the study

         12. Any other surgery in treated area within 12 months of initial treatment or during the
             course of the study

         13. History of keloid formation or poor wound healing in a previously injured skin area

         14. History of epidermal or dermal disorders (particularly if involving collagen or
             microvascularity)

         15. Open laceration or abrasion of any sort on the area to be treated

         16. Active Herpes Simplex I at the time of treatment

         17. Multiple dysplastic nevi in the area to be treated

         18. Having a bleeding disorder or taking anticoagulation medications, including heavy use
             of aspirin, in a manner which does not allow for a minimum 10 day washout period prior
             to the treatment (as per the subject 's physician discretion)

         19. History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or use of immunosuppressive medications

         20. Having any form of active cancer at the time of enrollment and during the course of
             the study

         21. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state
             that in the opinion of the Investigator would interfere with the anesthesia,
             treatment, or healing process

         22. Participation in a study of another device or drug within 1 month prior to study
             enrollment or during this study, and as per the Investigator's careful discretion, as
             long as not contradictory to any of the above criteria

         23. Tattoos, including cosmetic make-up tattoos, in the treatment area

         24. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse

         25. Any condition which, in the Investigator's opinion, would make it unsafe (for the
             subject or for the study personnel) to treat the subject as part of this research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan H Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Board Certified Plastic Surgeon, American Board of Plastic Surgeons</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Board Certified Dermatologist, American Board of Medical Specialties</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason N Pozner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Board Certified Plastic Surgeon, American Board of Plastic Surgeons</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanctuary Medical Aesthetic Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Paquet</last_name>
      <phone>561-886-0970</phone>
      <email>dpaquet28@aol.com</email>
    </contact>
    <investigator>
      <last_name>Jason N Pozner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Maryland Laser, Skin and Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cosmetic &amp; Reconstructive Plastic Surgery</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindi Godt, RN</last_name>
      <phone>516-498-2804</phone>
    </contact>
    <investigator>
      <last_name>Alan H Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wrinkle Reduction</keyword>
  <keyword>Skin Resurfacing</keyword>
  <keyword>Skin Texture Improvement</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

